Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach.
Avsar O
Nucleosides, Nucleotides & Nucleic Acids, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M et al.
European Journal of Human Genetics : Ejhg, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Benchmarking analysis of deleterious SNP prediction tools on CYP2D6 enzyme.
Ferreira KCDV et al.
Chemical Biology & Drug Design, 2020
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report.
Gaedigk A et al.
Pharmacogenomics, 2017
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX et al.
Drug Metabolism Reviews, 2015
Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.
Ruaño G et al.
Biomarkers in Medicine, 2013
The relative timing of mutations in a breast cancer genome.
Newman S et al.
Plos One, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T et al.
Current Drug Metabolism, 2011
Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Zembutsu H et al.
Expert Review of Anticancer Therapy, 2011
Genetic analysis of the rhabdomyolysis-associated genes in forensic autopsy cases of methamphetamine abusers.
Matsusue A et al.
Legal Medicine (tokyo, Japan), 2011
Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q et al.
The Pharmacogenomics Journal, 2009
New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B et al.
Drug Metabolism Reviews, 2009
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clinical Pharmacokinetics, 2009
The genomic landscapes of human breast and colorectal cancers.
Wood LD et al.
Science (new York, N.y.), 2007
The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
Narimatsu S et al.
Chemico-biological Interactions, 2006
The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH et al.
Journal of Human Genetics, 2006
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
Change in enantioselectivity in bufuralol 1''-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6.
Masuda K et al.
Chirality, 2005
Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T et al.
Brain Research. Molecular Brain Research, 2004
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2004
Alteration in catalytic properties of human CYP2D6 caused by substitution of glycine-42 with arginine, lysine and glutamic acid.
Tsuzuki D et al.
Drug Metabolism and Pharmacokinetics, 2003
Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae.
Tsuzuki D et al.
Pharmacogenetics, 2001
Pharmacogenetics in the practice of laboratory medicine.
Linder MW et al.
Molecular Diagnosis : a Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology, 1999
Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
Wormhoudt LW et al.
Critical Reviews in Toxicology, 1999